AndhraNews.net
Home » Business News » 2013 » November » November 25, 2013

Vista Partners Initiates Coverage on Targeted Medical Pharma (OTCQB:TRGM). - Video Research Alert on InvestmentPitch.com


November 25, 2013 - London

Vancouver, British Columbia, November 25, 2013 - San Francisco-based Vista Partners has initiated coverage on Targeted Medical Pharma (OTCQB:TRGM). Following the release of the company's 3rd quarter financial results, Analyst Ross Silver gives the company a 12 month target price of $2.75, a premium of 248% to the $0.79 price the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about Targeted Medical Pharma based on this report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Targeted Medical" in the search box.

The company reported total revenue of $6.9 million for the nine months ending September 30, 2013, an increase of 41% over the nine months ended September 30, 2012.

The company is a Los Angeles-based biotechnology company that develops and commercializes nutrient-based and pharmaceutical therapeutic systems.

Its patented prescription medical food products for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders,  are currently sold in the United States, to pharmacies through a network of distributors, and directly to physicians, who dispense medical foods and other pharmaceutical products through their office practices.

The company manufacturers 10 proprietary medical foods, and recently launched its first dietary supplement, "Clearwayz".

Analyst Ross Silver stated, "The company currently sells into 34 states and is looking to sell into all 50 and plans to expand into international markets. The U.S. market projected to be $2 billion plus and growing 10%+ annually."

The company currently trades at $1.00, below the $2.75 target price, and with 23.9 million shares outstanding, the company is capitalized at $23.9 million. For more information, please visit the company's website www.tmedpharma.com or call 310-474-9809.

The company's investor relations is handled by Jeff Ramson of ProActive Capital Group. He can be reached at 646-863-6983 or by email at jramson@proactivecapital.com.

For more information about Vista Partners or to obtain a copy of their research report, contact your nearest Vista Partners office. Their branches are listed on their website at www.vistapglobal.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing corporate interviews and three minute videos based on news releases and research reports. Please visit InvestmentPitch.com and browse our extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com





This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire

HUG#1745580

GlobeNewswire

Comment on this story

Share